NPP BrainPod Titelbild

NPP BrainPod

NPP BrainPod

Von: Springer Nature
Jetzt kostenlos hören, ohne Abo

ZEITLICH BEGRENZTES ANGEBOT. Nur 0,99 € pro Monat für die ersten 3 Monate. 3 Monate für 0,99 €/Monat, danach 9,95 €/Monat. Bedingungen gelten. Jetzt starten.

Über diesen Titel

BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology.

Hosted on Acast. See acast.com/privacy for more information.

American College of Neuropsychopharmacology
Wissenschaft
  • Older and wiser? The neural correlates of worry induction and reappraisal in older adults
    Oct 27 2025

    Worry seems like something most people do from time to time, but for some people, severe worry can become an overwhelming sensation, and for older adults later in life, severe worry has been associated with an increased risk of stroke and coronary heart disease. Carmen Andreescu is a professor of psychiatry and bioengineering at the University of Pittsburgh School of Medicine. She says mild worry is useful evolutionarily, to help us make plans or adapt behavior.


    Read the full study here: https://www.nature.com/articles/s41386-025-02193-1

    Hosted on Acast. See acast.com/privacy for more information.

    Mehr anzeigen Weniger anzeigen
    10 Min.
  • Grey matter morphometry in young adult e-cigarette users, tobacco cigarette users & non-using controls
    Jul 29 2025

    There’s been a fair amount of animal data suggesting that nicotine can affect the developing brain, but there hadn’t been the equivalent human studies done on people whose brains are still developing. And today there are two predominant forms of nicotine delivery - tobacco cigarettes, and e-cigarettes, or vaping.


    Laurie Zawertailo is a senior scientist at the Center for Addiction and Mental Health in Toronto and an associate professor in the department of pharmacology and toxicology at the University of Toronto. Kanwar Boparai recently completed her PhD, working with Dr. Zawertailo, and is now a postdoc. For their new study, they and some colleagues recruited young adults age 18-25, and these people fell into three groups: one that had only smoked cigarettes, one that had only ever vaped, and a third that functioned as a control, that had never used either. They ended up with 26 smokers, 27 vapers, and 25 controls. This is the first human study to separate cigarette smokers and vapers into distinct groups.


    Read the full study here: https://www.nature.com/articles/s41386-025-02086-3

    Hosted on Acast. See acast.com/privacy for more information.

    Mehr anzeigen Weniger anzeigen
    9 Min.
  • Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records
    Jun 4 2025

    Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine.


    Read the full study here: https://www.nature.com/articles/s41386-025-02062-x

    Hosted on Acast. See acast.com/privacy for more information.

    Mehr anzeigen Weniger anzeigen
    10 Min.
Noch keine Rezensionen vorhanden